Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo-Reference-Cited by-同舟云学术

Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo

Published:2017-01-31 Issue:10 Volume:31 Page:2020-2028
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Chaturvedi A,Herbst L,Pusch S^ORCID,Klett L,Goparaju R,Stichel D,Kaulfuss S,Panknin O,Zimmermann K,Toschi L,Neuhaus R,Haegebarth A,Rehwinkel H,Hess-Stumpp H,Bauser M,Bochtler T,Struys E A,Sharma A,Bakkali A,Geffers R,Araujo-Cruz M M,Thol F,Gabdoulline R,Ganser A,Ho A D,von Deimling A,Rippe K,Heuser M,Krämer A

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

https://www.nature.com/articles/leu201746.pdf

Reference37 articles.

1. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321: 1807–1812.

2. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360: 765–773.

3. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009; 361: 1058–1066.

4. Green A, Beer P . Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N Engl J Med 2010; 362: 369–370.

5. Thol F, Weissinger EM, Krauter J, Wagner K, Damm F, Wichmann M et al. IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica 2010; 95: 1668–1674.

Cited by 98 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biostructural, biochemical and biophysical studies of mutant IDH1;Nature Communications;2024-09-09

2. Development of Machine Learning-based QSAR Models for the Designing of Novel Anti-cancer Therapeutics Against Malignant Glioma;2024-08-19

3. The Alliance Between the German Cancer Research Center and Bayer: A Retrospective of an Innovative Collaboration Model;Handbook of Experimental Pharmacology;2024

4. Advances in the Delivery and Development of Epigenetic Therapeutics for the Treatment of Cancer;Molecular Pharmaceutics;2023-10-30

5. Targeting metabolic vulnerabilities to overcome resistance to therapy in acute myeloid leukemia;Cancer Drug Resistance;2023-08-17